Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLID.L Regulatory News (LID)

  • There is currently no data for LID

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI)

6 Nov 2020 11:03

RNS Number : 5324E
Nplus1 Singer Capital Markets Ltd
06 November 2020
 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Nplus1 Singer Capital Markets Limited

 

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

LiDCO Group Plc

(c) Name of the party to the offer with which exempt principal trader is connected:

LiDCO Group Plc

(d) Date dealing undertaken:

05 November 2020

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?

If it is a cash offer or possible cash offer, state "N/A"

NO

 

If YES, specify which:

 

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

 

ORD 0.5P

 

 

Sale

 

350,000

 

11.828p

 

11.6755p

 

ORD 0.5P

 

 

Purchase

 

466,744

 

11.7005p

 

11.6755p

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

Date of disclosure:

06 November 2020

Contact name:

Sarah-Rose Perry, Jennifer Bentick

Telephone number:

020 7496 3093

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FERGZMGMMVZGGZM
Date   Source Headline
26th Jan 20064:38 pmPRNConvertible loan update
19th Jan 20067:00 amRNSProduct Development
19th Dec 20051:15 pmPRNResignation of a Director
8th Dec 20059:02 amPRNDirector Shareholding
18th Nov 20057:00 amRNSConversion of Loan
8th Nov 20057:01 amRNSPositive Study Data
3rd Nov 20057:00 amRNSUS Army Order
25th Oct 20057:01 amRNSClinical Advisory Board
18th Oct 20057:01 amRNSInterim Results
14th Oct 20051:39 pmPRNDirectorate Change
26th Sep 20059:11 amRNSNotice of Results
11th Aug 20057:02 amRNSUSD 2 Million Financing
14th Jul 20057:00 amRNSAdditional Listing
7th Jul 20057:01 amRNSNew Veterinary Application
23rd Jun 20054:00 pmRNSImpact of Review Paper
17th Jun 20057:00 amRNSBoard Appointment
16th Jun 20052:57 pmRNSAGM Statement
6th Jun 20052:38 pmPRNDirector Shareholding
1st Jun 20057:00 amRNSPositive Data
10th May 20052:20 pmPRNDirector Shareholding
9th May 20057:00 amRNSRegistration in Brazil
25th Apr 20057:00 amRNSAppointment of New Director
15th Apr 200511:46 amRNSDirector Shareholding
13th Apr 20057:00 amRNSDirector Share Options Award
7th Apr 20057:00 amRNSDirector Shareholding
30th Mar 20057:01 amRNSPreliminary Results
30th Mar 20057:01 amRNSProduct Approval in Denmark
24th Mar 20057:02 amRNSLaunch Of Software Upgrade
23rd Mar 200510:50 amPRNAdditional Listing
21st Mar 20057:02 amRNSSignificant Trial Results
15th Mar 20057:02 amRNSEuropean Approval
2nd Mar 20058:19 amRNSChange of Financial PR Agency
14th Feb 20057:00 amPRNMajor Clinical Trial
24th Jan 20053:25 pmPRNAdditional Listing
19th Jan 20054:16 pmPRNDirectorate Change
13th Jan 200511:28 amPRNAdditional Listing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.